Objectives:According to our previous experience,Type III Nerve-sparing Radical hysterectomy (NSRH) for cervical cancer presented an acceptable urologic morbidity,without compromising radicality. The aim of this study ...Objectives:According to our previous experience,Type III Nerve-sparing Radical hysterectomy (NSRH) for cervical cancer presented an acceptable urologic morbidity,without compromising radicality. The aim of this study was to compare Type NSRH with other types of RH in terms of incidence of early bladder dysfunctions and perioperative complications. Methods:One hundred and ten patients with cervical cancer were submitted to Type II RH (group 1),Type III NSRH (group 2) and Type III RH (group 3). We assessed the postoperative early bladder function and complications. The follow-up period was 3 months. Results:Group 1 had a significantly shorter duration of the surgery,minor mean blood loss and shorter mean length of postoperative stay when compared to groups 2 and 3. No intraoperative complications were reported in either of the groups. The groups did not differ significantly in terms of G III/IV morbidity (group 1 = 10%,group 2 = 10%and group 3 = 15%,χ2,P value:0.65). Not even they differed in terms of urologic GI-IV morbidity (group 1 = 13%,group 2 = 15%and group 3 = 10%,χ2,P value = 0.88). Groups 1 and 2 presented a prompt recover of bladder function,significantly different from that of group 3. There was a significant difference between the groups regarding the number of patients discharged with selfcatheterism (group 1 = 0; group 2 and group 3 = 11; χ2,P value 0.05). Conclusions:The Type III NSRH seems to be comparable to Type II RH and superior to Type III RH in terms of early bladder dysfunctions.展开更多
我国很多医疗单位自20世纪90年代逐步开始应用肉毒毒素(botulinum toxin,BTX)治疗下尿路功能障碍性疾病的尝试,并取得了临床经验,获得了大量真实世界数据与证据。在国外,BTX治疗难治性膀胱过度活动症(overactive bladder,OAB)的适应证已...我国很多医疗单位自20世纪90年代逐步开始应用肉毒毒素(botulinum toxin,BTX)治疗下尿路功能障碍性疾病的尝试,并取得了临床经验,获得了大量真实世界数据与证据。在国外,BTX治疗难治性膀胱过度活动症(overactive bladder,OAB)的适应证已于2013年获得美国食品和药品监督管理局(Food and Drug Administration,FDA)批准,膀胱壁注射BTX治疗难治性OAB获得欧洲泌尿外科学会(European Association of Urology,EAU)和美国泌尿外科学会(American Urological Association,AUA)指南的高级别推荐(Ⅰ级证据、A级推荐)。但我国在该领域的临床应用仍属于有大量临床需求的"超适应证"使用,也没有制订出BTX在该领域应用的指南与共识。为提高我国BTX在该领域应用的合理性、合规性和规范性,更好地为众多患者提供精准的规范化治疗,造福更多中国患者,在中华医学会泌尿外科学分会尿控学组的领导下,组织国内本领域专家特制订此共识。展开更多
文摘Objectives:According to our previous experience,Type III Nerve-sparing Radical hysterectomy (NSRH) for cervical cancer presented an acceptable urologic morbidity,without compromising radicality. The aim of this study was to compare Type NSRH with other types of RH in terms of incidence of early bladder dysfunctions and perioperative complications. Methods:One hundred and ten patients with cervical cancer were submitted to Type II RH (group 1),Type III NSRH (group 2) and Type III RH (group 3). We assessed the postoperative early bladder function and complications. The follow-up period was 3 months. Results:Group 1 had a significantly shorter duration of the surgery,minor mean blood loss and shorter mean length of postoperative stay when compared to groups 2 and 3. No intraoperative complications were reported in either of the groups. The groups did not differ significantly in terms of G III/IV morbidity (group 1 = 10%,group 2 = 10%and group 3 = 15%,χ2,P value:0.65). Not even they differed in terms of urologic GI-IV morbidity (group 1 = 13%,group 2 = 15%and group 3 = 10%,χ2,P value = 0.88). Groups 1 and 2 presented a prompt recover of bladder function,significantly different from that of group 3. There was a significant difference between the groups regarding the number of patients discharged with selfcatheterism (group 1 = 0; group 2 and group 3 = 11; χ2,P value 0.05). Conclusions:The Type III NSRH seems to be comparable to Type II RH and superior to Type III RH in terms of early bladder dysfunctions.
文摘我国很多医疗单位自20世纪90年代逐步开始应用肉毒毒素(botulinum toxin,BTX)治疗下尿路功能障碍性疾病的尝试,并取得了临床经验,获得了大量真实世界数据与证据。在国外,BTX治疗难治性膀胱过度活动症(overactive bladder,OAB)的适应证已于2013年获得美国食品和药品监督管理局(Food and Drug Administration,FDA)批准,膀胱壁注射BTX治疗难治性OAB获得欧洲泌尿外科学会(European Association of Urology,EAU)和美国泌尿外科学会(American Urological Association,AUA)指南的高级别推荐(Ⅰ级证据、A级推荐)。但我国在该领域的临床应用仍属于有大量临床需求的"超适应证"使用,也没有制订出BTX在该领域应用的指南与共识。为提高我国BTX在该领域应用的合理性、合规性和规范性,更好地为众多患者提供精准的规范化治疗,造福更多中国患者,在中华医学会泌尿外科学分会尿控学组的领导下,组织国内本领域专家特制订此共识。
